March 13, 2023
STAT: The second age of psychedelic therapies for mental health

February 22, 2023
Leafly: Can psychedelic mushrooms trigger psychosis?

February 16, 2023
Bioworld: Trip wire: News due soon from varied developers in psychedelic space could trigger still more interest

February 14, 2023
Green Market: Reunion Neuroscience Reports Earnings, Update on Postpartum Drug Study

February 14, 2023
Benzinga: Reunion Neuroscience Touts ‘Transformative’ Quarter, Reaffirms Postpartum Depression Treatment

January 24, 2023
Behavioral Health Business: Why 2023 Could be a Pivotal Year for Psychedelic-Assisted Treatment

January 18, 2023
MarketWatch: Reunion Neuroscience Taps Robert Alexander as Chief Medical Officer

January 18, 2023
Wall Street Journal: Reunion Neuroscience Taps Robert Alexander as Chief Medical Officer

January 18, 2023
Becker’s Physician Leadership / Becker’s Hospital Review: Former Pfizer, Merck executive joins Reunion Neuroscience

January 18, 2023
Seeking Alpha: Reunion Neuroscience appoints Robert Alexander as Chief Medical Officer

January 16, 2023
HIT Consultant: 22 Executive Digital Health Predictions to Watch in 2023

January 16, 2023
Psychedelic Invest: Greg Mayes, CEO of Reunion, Sits in the Investor Hotseat on January 16th

January 13, 2023
Psychedelic Invest: Greg Mayes, CEO of Reunion, Sits in the Investor Hotseat on January 16th

January 10, 2023
Psychedelic Health: Psychedelic compound shown to be safe in postpartum trial

January 9, 2023
Benzinga: Could This New Psychedelic Substance Help Treat Postpartum Depression? Researchers Aim To Find Out

January 9, 2023
Green Market Report: Postpartum Depression Psychedelic Treatment Studied In Reunion’s Phase 1 Trial

January 9, 2023
Psychedelic Invest: Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

January 6, 2023
Green Market Report: An Objective Look at the Psychedelics Industry for 2023

January 3, 2023
Green Market Report: 2023 Will Be The Breakout Year for Psychedelics

December 21, 2022
Green Market Report / Psychedealia: How 5 Psychedelics Companies Fared in 2022

December 18, 2022
Wall Street Journal: Drug Companies Join Medical Psychedelic Movement—But Without the High

December 1, 2022
Life Science Leader: Will The Finance And Funding Pendulum Swing Back To Black In 2023?

November 23, 2022
Psychiatric Times: Promising New Treatments For Postpartum Depression

October 28, 2022
Endpoints News: Peer Review

October 26, 2022
Fortune: CFO Daily Newsletter

October 24, 2022
BioWorld: Appointments And Advancements

October 24, 2022
Psychedelic Invest: Reunion Neuroscience Appoints Chief Financial Officer And Vice President, Medical Affairs

October 13, 2022
The Fly: Reunion CEO, CSO Talk Psychedelic Drug Development, Challenges, Opportunities, And More

September 30, 2022
Endpoints News: Peer Review

September 29, 2022
Drug Discovery & Development: An Inside Look At Reunion Neuroscience’s Psychedelic Strategy For Treating Depression

September 29, 2022
Psychedelic Invest: Reunion Neuroscience Inc. Appoints Greg Mayes As President And Chief Executive Officer

September 28, 2022
Seeking Alpha: Reunion Neuroscience Appoints Greg Mayes As President And CEO

September 28, 2022
Drug Discovery & Development: Reunion Neuroscience Names New CEO To Guide Development Of Psychedelic Depression Therapy

September 28, 2022
MarketWatch: Reunion Neuroscience Names Mayes As President, CEO